Is PT-141 (Bremelanotide) Legal in Florida?
HealthRX.com
Vyleesi is prescription-only; research PT-141 is not approved
See the public record for Bremelanotide
At a glance
- FDA status / Approved as Vyleesi, NDA 210557, June 21, 2019 [1][2]
- Prescription status / Prescription only; 1.75 mg subcutaneous autoinjector [1]
- Approved for / Premenopausal women with acquired, generalized HSDD [1]
- Not indicated for / Men, postmenopausal women, or enhancing sexual performance [1]
- Boxed warning / None; no REMS in the label or the 2019 approval letter [1][2]
- Research or compounded PT-141 / Not Vyleesi; not FDA-approved drugs [5][1]
- Florida framework / Chapter 499 (drugs) and Chapter 458 (medical practice); neither listing names bremelanotide [3][4]
Vyleesi is FDA-approved and available by prescription
FDA approved Vyleesi on June 21, 2019 under NDA 210557; the current holder is Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous autoinjector, prescription only, with no boxed warning and no risk evaluation and mitigation strategy in the label or in the 2019 approval letter [1][2].
What Vyleesi is approved to treat
The labeled use is premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD): low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1].
Vyleesi is not indicated for HSDD in postmenopausal women or in men, and is not indicated to enhance sexual performance [1].
What a prescription involves
The labeled dose is 1.75 mg subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours. The label says more than 8 doses per month is not recommended, and that treatment should stop after 8 weeks if symptoms have not improved [1]. The label contraindicates Vyleesi in uncontrolled hypertension or known cardiovascular disease and does not recommend it in patients at high risk of cardiovascular disease [1]. Each dose transiently raises blood pressure, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after the dose [1]. In pooled phase 3 trials, nausea occurred in 40.0% versus 1.3% on placebo and flushing in 20.3% versus 0.3% [1].
The PT-141 sold online is a different product
Vials marketed as PT-141 for research use, and bremelanotide prepared by a compounding pharmacy, are not Vyleesi and are not FDA-approved drugs; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [5][1]. Bremelanotide does not appear on FDA's list of bulk drug substances that may present significant safety risks, in any category on FDA's bulk-substance lists, or among the six peptides in HHS's October 2026 draft enforcement-discretion policy [6][7][8].
Questions worth asking
What Florida's drug and medical-practice chapters cover
Florida's drug law is the Florida Drug and Cosmetic Act, Chapter 499, and medical practice is governed by Chapter 458 [3][4]. The cited pages are broad listings of the parts of the drug act and the sections of the medical practice statute, and neither names bremelanotide [3][4]. This page therefore does not establish whether research-use or compounded PT-141 products may be sold or prescribed in Florida.
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is PT-141 legal in Florida?
Can you buy PT-141 without a prescription?
Is bremelanotide approved for men?
What does a Vyleesi prescription involve?
References
Show all 8 referencesHide references
- U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
- U.S. Food and Drug Administration.
- Chapter 499 - 2023 Florida Statutes - The Florida Senate.
- Chapter 458 - 2023 Florida Statutes - The Florida Senate.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- Official web page.